Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

3,741

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

3,741 results for “Hormons”

Learn how ShareScore rates datasets ↗
geo12/100

Nuclear translocation of PTH receptor hijacks thyroid hormone signaling for bone mass regulation [RNA-seq]

GEO Series GSE233172. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2023View details →
geo12/100

Hormonal Regulation of MicroRNA Expression in Rat Adrenal Gland

GEO Series GSE47131. Rattus norvegicus; synthetic construct. 12 samples. Type: Expression profiling by array.

openGEO-OpenMay 2014View details →
geo12/100

Adipocyte thyroid hormone receptor β determines the intracellular usage and fate of glucose and governs systemic homeostasis

GEO Series GSE205520. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJun 2025View details →
geo12/100

Genome wide analysis of circulating miRNAs in growth hormone secreting pituitary neuroendocrine tumor patients' plasma

GEO Series GSE196647. Homo sapiens. 83 samples. Type: Non-coding RNA profiling by high throughput sequencing.

openGEO-OpenFeb 2022View details →
geo12/100

Parathyroid Hormone Receptor-1 Signaling Aggravates Hepatic Fibrosis through Upregulating cAMP Response Element Binding Protein-Like 2

GEO Series GSE227904. Homo sapiens; Mus musculus. 14 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2023View details →
zenodo12/100

Dataset related to article "Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production "

<p>This record contains raw data related to article &quot;Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production&quot;</p> <p><strong>Purpose: </strong> The purpose of this study was to assess prospectively the efficacy and safety of stereotactic body radiation therapy (SBRT) for adrenal gland metastasis, with a focus on the assessment of the irradiated subjects&#39; endocrinological function.</p> <p><strong>Materials and methods: </strong> A total of 36 patients were enrolled from 2017 to 2020 in this prospective phase II trial. Patients were treated with Linac-based SBRT, with a dose of 45 Gy in 3 consecutive fractions. Primary end-point was local control (LC) of the treated lesions and secondary end-points included evaluation of acute and late toxicity, progression free survival (PFS), overall survival (OS) and the impact on the hormonal production of adrenal glands.</p> <p><strong>Results: </strong> With a median follow-up of 9.5 months, LC rates at 1 and 2 years were 94.7% and 88.4%, respectively. Rates of PFS at 1 and 2 years were 50.5% and 29.8%, with a median PFS of 14.7 months. Rates of OS at 1 and 2 years were 62.9% and 44.1%. At univariate analysis, oligorecurrence was associated with better OS compared to oligoprogressive or synchronous metastatic disease. No grade 3 or greater toxicities were registered and only a minority of patients (22.2%) reported mild treatment-related side effects. Hormonal and electrolytes production was assessed before and after treatment, showing only a slight and transient variation within the reference ranges.</p> <p><strong>Conclusion: </strong> SBRT on adrenal metastases has been confirmed to be a feasible and effective treatment. With an excellent disease control and the preservation of the endocrine function, SBRT with ablative dose can be considered a viable alternative to more invasive approaches.</p>

restrictedFeb 2022View details →
zenodo12/100

Dataset related to article "Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?"

<p>&nbsp;This record contains raw data related to article &ldquo;Is Anti-M&uuml;llerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?&quot;</p> <p><strong><em>Introduction:</em></strong> Anti-M&uuml;llerian hormone (AMH) is the most reliable biomarker of ovarian reserve; however, its role in predicting ovarian recovery after chemotherapy is unclear. Administration of a GnRH analog (GnRHa) during chemotherapy significantly reduces the ovarian failure rate and increases the pregnancy rate. The available data on the behavior of AMH during concurrent administration of chemotherapy and GnRHa are inconsistent. We investigated whether concurrent administration of triptorelin and adjuvant chemotherapy might reduce the expected drop of AMH. <strong><em>Methods:</em></strong> Eligible patients were premenopausal women aged &lt;40 years, with a diagnosis of early breast cancer, and candidates to 4&ndash;8 cycles of adjuvant chemotherapy. Triptorelin (3.75 mg i.m.) was started before chemotherapy and administered every 4 weeks thereafter. The principal endpoint was the proportion of patients with an AMH percent change &le;50% between 12 months after chemotherapy and basal levels. The secondary endpoint was the proportion of patients achieving postchemotherapy AMH levels above the threshold of 0.2 ng/mL. <strong><em>Results:</em></strong> Fifty patients were enrolled, 31 of whom had blood samples available at baseline and 1 year after the end of chemotherapy. AMH decreased to nearly undetectable levels after chemotherapy and recovered after 12 months, but they did not exceed 1 tenth of the pretreatment levels. As for the secondary endpoint, 15 of the 31 patients recovered AMH levels above the threshold. <strong><em>Conclusions:</em></strong> This study did not reach its principal endpoint; however, the rate of 48% of patients who recovered AMH above threshold levels favorably compared with those in studies without concurrent GnRHa, supporting a better recovery of AMH with triptorelin.</p>

restrictedFeb 2022View details →
zenodo12/100

Dataset related to article "Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer"

<p>This record contains raw data related to article &ldquo;Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer&quot;</p> <p>Abstract</p> <p>We retrospectively investigated in women treated with fulvestrant for HR+/HER2 negative advanced breast cancer clinical, pathological and molecular features associated with long-term benefit from treatment defined as being progression-free at 18 months. Specifically, we analyzed on formalin-fixed paraffin-embedded tumor samples ESR1 and PI3KCA mutations and miRNAs profiles. 59 patients were evaluable (median age of 67 years, range 32-92). 18-month PFS rate was 27%; the lack of visceral metastases significantly predicted the likelihood of being progression-free at 18 months, while PI3KCA mutations, found in 36% of patients, were not associated with 18-month PFS. As of miRNAs, miR-549a, miR-644a, miR-16-5p were negatively while let-7c-5p was positively associated with 18-month PFS. In addition, miR-520d-3p and miR-548g-3p values were significantly lower while miR-603, miR-181a-5p and miR-199a-miR-199b-3p values were significantly higher in patients achieving 18-month PFS. In silico analysis of targets modulated by these two latter groups of miRNAs show that in patients achieving 18-month PFS the Hippo and Wnt signaling pathways were predicted to be upregulated while endocrine resistance was potentially repressed by miR-603, miR-181a-5p and miR-199a-miR-199b-3p. Our results provide additional clues on the molecular mechanisms involved in fulvestrant activity and resistance. Underlying pathways should be further elucidated and confirmed in larger cohorts</p>

restrictedFeb 2023View details →
zenodo12/100

Comparing Effects of Ultra Low Dose (Ethinyl Estradiol 20µg or 15µg) with Low Dose (Ethinyl Estradiol 30µg) Hormonal Pills on Lipid Discordance in Non-Obese PCOS Women: A Randomized Control Trial

<p>Ultra-low dose hormonal pills have become the favoured treatment option over low dose pills in PCOS. Existing literature shows marked heterogeneity in metabolic effects of pills with different compositions. This might have been due to improper choice of outcome variable for comparison. Total cholesterol - high density lipoprotein ratio (TC/HDL) discordance with Low Density Lipoprotein cholesterol (LDL-C) was a better marker of future risk of atherosclerotic cardio-vascular disease and stable to variations. Present study was a randomised controlled trial conducted to compare prevalence of TC/HDL and LDL discordance among non-obese PCOS women treated with hormonal pills of different compositions. Role of baseline participant features and pill composition on discordance after treatment was determined. Women were randomised into three arms, two arms receiving ultra-low dose pills (either Ethinyl Estradiol 20&micro;g with drosperinone 3mg or Ethinyl Estradiol 15&micro;g with gestodene 60&micro;g) and one arm receiving low dose pill (Ethinyl Estradiol 30&micro;g with desogestrel 150 &micro;g). Discordance was observed in more than 1/4<sup>th</sup> participants prior to intervention. After one year of treatment less than 1/5<sup>th</sup> of participants were discordant. Ultra-low dose pill users had lower discordance, LDL and TC compared to low dose pill users after one year of treatment. Random Forest a non-linear classifier showed the highest accuracy in predicting discordance. Baseline Parameters having maximal impact on occurrence of discordance were triglyceride (TG), HOMA-IR, BMI and HDL.Ultra-low dose hormonal pills have become the favoured treatment option over low dose pills in PCOS. Existing literature shows marked heterogeneity in metabolic effects of pills with different compositions. This might have been due to improper choice of outcome variable for comparison. Total cholesterol - high density lipoprotein ratio (TC/HDL) discordance with Low Density Lipoprotein cholesterol (LDL-C) was a better marker of future risk of atherosclerotic cardio-vascular disease and stable to variations. Present study was a randomised controlled trial conducted to compare prevalence of TC/HDL and LDL discordance among non-obese PCOS women treated with hormonal pills of different compositions. Role of baseline participant features and pill composition on discordance after treatment was determined. Women were randomised into three arms, two arms receiving ultra-low dose pills (either Ethinyl Estradiol 20&micro;g with drosperinone 3mg or Ethinyl Estradiol 15&micro;g with gestodene 60&micro;g) and one arm receiving low dose pill (Ethinyl Estradiol 30&micro;g with desogestrel 150 &micro;g). Discordance was observed in more than 1/4<sup>th</sup> participants prior to intervention. After one year of treatment less than 1/5<sup>th</sup> of participants were discordant. Ultra-low dose pill users had lower discordance, LDL and TC compared to low dose pill users after one year of treatment. Random Forest a non-linear classifier showed the highest accuracy in predicting discordance. Baseline Parameters having maximal impact on occurrence of discordance were triglyceride (TG), HOMA-IR, BMI and HDL.</p>

restrictedJul 2023View details →
geo12/100

Prediction of Auxin-Ethylene Crosstalk Mediators Using Meta-Analysis of Hormone-Induced Transcriptome Data in Arabidopsis

GEO Series GSE149410. Arabidopsis thaliana. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2020View details →
geo12/100

Thyroid hormone receptor beta1 action in the resolution of liver fibrosis

GEO Series GSE223882. Mus musculus. 32 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJun 2025View details →
geo12/100

Effect of Parathyroid Hormone Analog Treatment on Gene Expression

GEO Series GSE181344. Mus musculus. 21 samples. Type: Expression profiling by array.

openGEO-OpenAug 2022View details →
geo12/100

WFUBMC Primate Center X-96-23: Cynomolgus macaque response to hormone replacement therapy

GEO Series GSE27228. Macaca fascicularis; Macaca mulatta. 16 samples. Type: Expression profiling by array.

openGEO-OpenFeb 2011View details →
geo12/100

Leaf maturation transcriptional dynamics are plastic in response to stress (hormone data)

GEO Series GSE290214. Arabidopsis thaliana. 9 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenFeb 2025View details →
geo12/100

Thyroid hormone-responsive genes in primary cultures of rat hepatic cells

GEO Series GSE282664. Rattus norvegicus. 2 samples. Type: Expression profiling by array.

openGEO-OpenNov 2024View details →
geo12/100

Parathyroid Hormone Receptor-1 Signaling Aggravates Hepatic Fibrosis through Upregulating cAMP Response Element Binding Protein-Like 2 (human)

GEO Series GSE227902. Homo sapiens. 7 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2023View details →
geo12/100

Transcriptome of oviducts from non-hormonally stimulated mice

GEO Series GSE51614. Mus musculus. 9 samples. Type: Expression profiling by array.

openGEO-OpenJan 2015View details →
geo12/100

Androgen receptor is a back-door inhibitor of Androgen Receptor is a Backdoor Inhibitor of Wildtype and Mutant Estrogen Receptors in Refractory Hormone Receptor-Positive Breast Cancers

GEO Series GSE126318. Homo sapiens. 7 samples. Type: Expression profiling by array.

openGEO-OpenJul 2019View details →
geo12/100

Effect of Ovarian Hormone on Gene Expression in Rhesus Dorsal Raphe Nucleus with Rhesus Affymetrix Chip

GEO Series GSE16172. Macaca mulatta. 12 samples. Type: Expression profiling by array.

openGEO-OpenMay 2009View details →
zenodo8/100

Development and validation of a prediction model using sella magnetic resonance imaging-based radiomics and clinical parameters for diagnosis of growth hormone deficiency and idiopathic short stature: A multicenter, cross-sectional study

Open the record for dataset details and reuse information.

restrictedOct 2024View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.